Table 1.
Patient characteristics of 20 patients in phase 2 cohort and 12 patients in oral solution cohort.
Characteristic | Phase 2 (n = 20) |
Oral Solution (n = 12) |
---|---|---|
Median Age (Range), years | 10.7 (4.3–19.4) | 3.0 (1.6–7.2) |
Male : Female | 14 : 6 | 6 : 6 |
MYCN Amplified : Non-Amplified | 3 : 14 | 6 : 5 |
Prior Irinotecan | 11 (55%) | 2 (17%) |
Prior Temozolomide | 10 (50%) | 2 (17%) |
Median Number of Prior Regimens (Range) | 3 (1–10) | 1 (1–2) |
> 3 Prior Regimens | 8 (40%) | 0 (0%) |